Dual-Agonist GLP-1 GIP Composition for Reduced GI Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GLP-1 receptor agonists for treating type 2 diabetes (T2DM) often cause gastrointestinal adverse reactions such as nausea and vomiting, limiting their therapeutic effectiveness and requiring additional treatment schemes to enhance glucose lowering and weight loss.
Innovation Solution
A pharmaceutical composition comprising a GLP-1 analog with a dual-agonist effect on both GLP-1 and GIP receptors, formulated with a buffer, osmotic pressure regulator, pH adjuster, and bacteriostatic agent to enhance stability and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the dose of GLP-1 drugs is increased to achieve more remarkable treatment effects, then glucose lowering and weight loss effects are improved, but gastrointestinal adverse reactions occur more frequently
Solution Approach 1:
The patent combines GLP-1 receptor agonist activity with GIP receptor agonist activity into a single dual-agonist molecule. This merging of two therapeutic mechanisms allows achieving enhanced glucose lowering and weight loss effects without proportionally increasing GLP-1-related gastrointestinal side effects, as the GIP component contributes to metabolic improvement with better tolerability
Solution Approach 2:
The patent modifies the chemical structure of GLP-1 analogs by introducing specific amino acid substitutions and extensions (such as adding GIP receptor binding domains). These parameter changes in molecular structure enable the compound to activate both GLP-1 and GIP receptors, thereby improving the therapeutic effect-to-side effect ratio
2Quantity of substance
If chemically modified polypeptide drugs are used to enhance therapeutic effect, then treatment efficacy is improved, but stability during storage and use deteriorates
Solution Approach 1:
The patent systematically optimizes formulation parameters including pH (adjusted to specific ranges), ionic strength, excipient concentrations, and oxidation-reduction potential. These parameter changes create a controlled chemical environment that stabilizes the dual-agonist polypeptide against degradation, polymerization, and unwanted chemical modifications during storage and administration
Solution Approach 2:
The patent employs various excipients and additives as intermediary substances that protect the dual-agonist polypeptide from degradation. These intermediaries include buffering agents, osmotic pressure regulators, and stabilizing compounds that create a protective microenvironment, preventing direct interaction between the polypeptide and destabilizing factors
Data Source
AI summary
Provided are a pharmaceutical composition of a GLP-1 receptor and a GIP receptor dual agonist, and a use thereof. Specifically, the pharmaceutical composition comprises a GLP-1 analogue as shown in general formula (I), and a buffer such as a phosphate buffer; the composition may further comprise an osmoregulator such as propylene glycol, sodium chloride or mannitol. The pharmaceutical composition has good biological activity and stability. The general formula (I) is:R1-X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-X15-X16-X17-X18-X19-X20-Glu-Phe-X23-X24-Trp-Leu-X27-X28-X29-X30-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-R2. (I)